{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:04:18Z","timestamp":1791558258730,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["TBM Project T002218N"],"award-info":[{"award-number":["TBM Project T002218N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1136\/ijgc-2023-005229","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T13:20:47Z","timestamp":1715260847000},"page":"1217-1224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent\/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct03926936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05601700","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05601700","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03643510","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03643510","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05154487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05154487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05082025","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05082025","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6556-5203","authenticated-orcid":false,"given":"Rita","family":"Trozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Tuyaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Herreros Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Boog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Leunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Trum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5452-4905","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-005229_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030759","article-title":"Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications","volume":"14","author":"Mitra","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-005229_bb0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-005229_bb0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41391-018-0081-6","article-title":"Estrogens and prostate cancer","volume":"22","author":"Dobbs","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1136\/ijgc-2023-005229_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The CBIO cancer genomics portal: an open platform for exploring multidimensional cancer","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2023-005229_bb0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumour tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","article-title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","volume":"113","author":"Argenta","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0040","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.ejca.2013.08.005","article-title":"Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature","volume":"49","author":"van Kruchten","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-005229_bb0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of fulvestrant 250 mg\/month in patients with recurrent or metastatic endometrial cancer: a study of the arbeitsgemeinschaft gyn\u00e4kologische onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of fulvestrant in recurrent\/metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2005.09.011","article-title":"Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy","volume":"100","author":"Hoffman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0060","first-page":"577","article-title":"Fulvestrant: a further treatment option for patients with metastatic uterine cancer","volume":"29","author":"Lux","year":"2006","journal-title":"Onkologie"},{"key":"10.1136\/ijgc-2023-005229_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"Euroqol--a new facility for the measurement of health-related quality of life","volume":"16","author":"Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1136\/ijgc-2023-005229_bb0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2023-005229_bb0075","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2023-005229_bb0080","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1158\/1078-0432.CCR-07-0809","article-title":"Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer","volume":"13","author":"Pusztai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-005229_bb0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0090","article-title":"Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas","volume":"40","author":"Crowley","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2023-005229_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2019.04.010","article-title":"Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies","volume":"154","author":"Gaillard","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0100","unstructured":"Letrozole for estrogen\/progesterone receptor positive low-grade serous epithelial ovarian cancer (LEPRE trial) (LEPRE). NCT05601700. Available: https:\/\/clinicaltrials.gov\/study\/NCT05601700 [Accessed 26 Mar 2024]."},{"key":"10.1136\/ijgc-2023-005229_bb0105","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ijgc-2023-005189","article-title":"A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial","volume":"34","author":"Ottenbourgs","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005229_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2023-005229_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2258","article-title":"A randomised double-blind placebo-controlled phase II trial of Palbociclib combined with Letrozole (L) in patients (Pts) with oestrogen receptor-positive (ER+) advanced\/recurrent endometrial cancer (EC): NSGO-PALEO \/ ENGOT-En3 trial","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005229_bb0120","unstructured":"Evaluating cancer response to treatment with abemaciclib and fulvestrant in women with recurrent endometrial cancer (NCT03643510). Available: https:\/\/www.mycancergenome.org\/content\/clinical_trials\/NCT03643510\/ [Accessed 26 Mar 2024]."},{"key":"10.1136\/ijgc-2023-005229_bb0125","unstructured":"A study of alpelisib and fulvestrant to treat endometrial cancer. NCT05154487. Available: https:\/\/www.clinicaltrials.gov\/study\/NCT05154487 [Accessed 26 Mar 2024]."},{"key":"10.1136\/ijgc-2023-005229_bb0130","unstructured":"Phase 2 study of Pi3K inhibitor copanlisib in combination with fulvestrant in selected ER+ and\/or PR+ cancers with PI3K (PIK3CA, PIK3R1) and\/or PTEN alterations. NCT05082025. Available: https:\/\/clinicaltrials.gov\/study\/NCT05082025 [Accessed 26 Mar 2024]."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-005229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:27:03Z","timestamp":1764062823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1048891X24000057"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-005229","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent\/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-005229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}